These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 32884603)
1. Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19. Giri A; Das A; Sarkar AK; Giri AK Genes Environ; 2020; 42():25. PubMed ID: 32884603 [TBL] [Abstract][Full Text] [Related]
2. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395 [TBL] [Abstract][Full Text] [Related]
3. Chloroquine and Hydroxychloroquine: Efficacy in the Treatment of the COVID-19. Ho TC; Wang YH; Chen YL; Tsai WC; Lee CH; Chuang KP; Chen YA; Yuan CH; Ho SY; Yang MH; Tyan YC Pathogens; 2021 Feb; 10(2):. PubMed ID: 33671315 [TBL] [Abstract][Full Text] [Related]
4. Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties. Warhurst DC; Steele JC; Adagu IS; Craig JC; Cullander C J Antimicrob Chemother; 2003 Aug; 52(2):188-93. PubMed ID: 12837731 [TBL] [Abstract][Full Text] [Related]
5. Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents. Verbaanderd C; Maes H; Schaaf MB; Sukhatme VP; Pantziarka P; Sukhatme V; Agostinis P; Bouche G Ecancermedicalscience; 2017; 11():781. PubMed ID: 29225688 [TBL] [Abstract][Full Text] [Related]
6. A review on the pharmacokinetic properties and toxicity considerations for chloroquine and hydroxychloroquine to potentially treat coronavirus patients. Askarian F; Firoozi Z; Ebadollahi-Natanzi A; Bahrami S; Rahimi HR Toxicol Res; 2022 Apr; 38(2):137-148. PubMed ID: 34306523 [TBL] [Abstract][Full Text] [Related]
7. Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects? Zhan X; Dowell S; Shen Y; Lee DL Heliyon; 2020 Sep; 6(9):e04900. PubMed ID: 32935064 [TBL] [Abstract][Full Text] [Related]
8. Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use. Chen Y; Shen T; Zhong L; Liu Z; Dong X; Huang T; Wang Q; Xiao H Front Pharmacol; 2020; 11():1167. PubMed ID: 32848774 [TBL] [Abstract][Full Text] [Related]
10. Chloroquine and Hydroxychloroquine Use During Pregnancy and the Risk of Adverse Pregnancy Outcomes Using Real-World Evidence. Bérard A; Sheehy O; Zhao JP; Vinet E; Quach C; Bernatsky S Front Pharmacol; 2021; 12():722511. PubMed ID: 34408654 [No Abstract] [Full Text] [Related]
11. Evaluation of weak genotoxicity of hydroxychloroquine in human TK6 cells. Li X; Le Y; Li Y; Chen S; Guo L; Fu X; Manjanatha MG; Mei N Toxicol Lett; 2024 Mar; 393():84-95. PubMed ID: 38311193 [TBL] [Abstract][Full Text] [Related]
12. Differential effects of mepacrine, chloroquine and hydroxychloroquine on superoxide anion generation, phospholipid methylation and arachidonic acid release by human blood monocytes. Hurst NP; French JK; Bell AL; Nuki G; O'Donnell ML; Betts WH; Cleland LG Biochem Pharmacol; 1986 Sep; 35(18):3083-9. PubMed ID: 3019354 [TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine in rheumatic autoimmune disorders and beyond. Nirk EL; Reggiori F; Mauthe M EMBO Mol Med; 2020 Aug; 12(8):e12476. PubMed ID: 32715647 [TBL] [Abstract][Full Text] [Related]
14. Chloroquine and hydroxychloroquine inhibit bladder cancer cell growth by targeting basal autophagy and enhancing apoptosis. Lin YC; Lin JF; Wen SI; Yang SC; Tsai TF; Chen HE; Chou KY; Hwang TI Kaohsiung J Med Sci; 2017 May; 33(5):215-223. PubMed ID: 28433067 [TBL] [Abstract][Full Text] [Related]
15. Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19. Adeel AA Sudan J Paediatr; 2020; 20(1):4-9. PubMed ID: 32528194 [TBL] [Abstract][Full Text] [Related]
16. Long-term effectiveness of antimalarial drugs in rheumatic diseases. Aviña-Zubieta JA; Galindo-Rodriguez G; Newman S; Suarez-Almazor ME; Russell AS Ann Rheum Dis; 1998 Oct; 57(10):582-7. PubMed ID: 9893568 [TBL] [Abstract][Full Text] [Related]
17. Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. Picot S; Marty A; Bienvenu AL; Blumberg LH; Dupouy-Camet J; Carnevale P; Kano S; Jones MK; Daniel-Ribeiro CT; Mas-Coma S One Health; 2020 Jun; 9():100131. PubMed ID: 32292817 [TBL] [Abstract][Full Text] [Related]
18. A Simple Bayesian Method for Evaluating Whether Data From Patients With Rheumatic Diseases Who Have Been Under Chronic Hydroxychloroquine Medication Since Before the COVID-19 Outbreak Can Speak to Hydroxychloroquine's Prophylactic Effect Against Infection With SARS-CoV-2. Musca SC Front Med (Lausanne); 2020; 7():490. PubMed ID: 32903552 [TBL] [Abstract][Full Text] [Related]
19. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study. Mittal L; Zhang L; Feng R; Werth VP J Am Acad Dermatol; 2018 Jan; 78(1):100-106.e1. PubMed ID: 28989103 [TBL] [Abstract][Full Text] [Related]